No. In 2026, Novo Nordisk reported that two Phase 3 trials of semaglutide, the GLP-1 drug behind Ozempic and Wegovy, failed to slow cognitive decline in early Alzheimer’s across more than 3,0000 participants. At the ADPD 2026 conference, data presented showed no benefit to clinical trial participants.